A PYMNTS Company

Request To Create California Subclass In Lipitor Antitrust Case Refused

By  |  February 28, 2021

A federal judge has refused to create a California subclass within a nationwide proposed class action accusing Pfizer of obtaining a fraudulent patent and conspiring with generic drugmaker Ranbaxy to delay sales of generic versions of its cholesterol drug Lipitor.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    US District Judge Peter Sheridan in New Jersey on Friday, February 26, rejected an argument by two California residents who bought Lipitor that they needed a separate class because the lead plaintiffs, municipalities, and health plans, were third-party payors that did not take the drug themselves and so lacked standing to bring claims under California’s Cartwright Act, an antitrust law.

    The lawsuit, filed in 2012, stems from a 2008 settlement of a patent lawsuit filed by Pfizer against Ranbaxy over Ranbaxy’s plan to make generic Lipitor. Under the deal, Pfizer agreed to drop a claim for damages against Ranbaxy, and Ranbaxy agreed to stay out of the Lipitor market until November 2011.

    Retailers and distribution companies claim that the settlement amounted to Pfizer paying Ranbaxy to stay out of the Lipitor market, violating antitrust laws. But Sheridan ruled on Friday that their case failed because they did not offer any allegation of the settlement’s dollar value.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.